▲ +58.26% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for PAVmed in the last 3 months. The average price target is $6.75, with a high forecast of $9.00 and a low forecast of $5.00. The average price target represents a 58.26% upside from the last price of $4.27.
The current consensus among 4 investment analysts is to buy stock in PAVmed. This Buy consensus rating has held steady for over two years.
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.